328 related articles for article (PubMed ID: 2408276)
1. Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement.
Lambris JD; Ganu VS; Hirani S; Müller-Eberhard HJ
Proc Natl Acad Sci U S A; 1985 Jun; 82(12):4235-9. PubMed ID: 2408276
[TBL] [Abstract][Full Text] [Related]
2. Identification of a 145,000 Mr membrane protein as the C3d receptor (CR2) of human B lymphocytes.
Weis JJ; Tedder TF; Fearon DT
Proc Natl Acad Sci U S A; 1984 Feb; 81(3):881-5. PubMed ID: 6230668
[TBL] [Abstract][Full Text] [Related]
3. Evidence for multiple sites of interaction in C3 for complement receptor type 2 (C3d/EBV receptor, CD21).
Esparza I; Becherer JD; Alsenz J; De la Hera A; Lao Z; Tsoukas CD; Lambris JD
Eur J Immunol; 1991 Nov; 21(11):2829-38. PubMed ID: 1834472
[TBL] [Abstract][Full Text] [Related]
4. Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2)/CD21: identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface.
Guthridge JM; Young K; Gipson MG; Sarrias MR; Szakonyi G; Chen XS; Malaspina A; Donoghue E; James JA; Lambris JD; Moir SA; Perkins SJ; Holers VM
J Immunol; 2001 Nov; 167(10):5758-66. PubMed ID: 11698449
[TBL] [Abstract][Full Text] [Related]
5. Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection.
Carel JC; Myones BL; Frazier B; Holers VM
J Biol Chem; 1990 Jul; 265(21):12293-9. PubMed ID: 1695627
[TBL] [Abstract][Full Text] [Related]
6. Neoantigens in complement component C3 as detected by monoclonal antibodies. Mapping of the recognized epitopes by synthetic peptides.
Nilsson B; Nilsson Ekdahl K; Avila D; Nilsson UR; Lambris JD
Biochem J; 1990 May; 268(1):55-61. PubMed ID: 1693076
[TBL] [Abstract][Full Text] [Related]
7. Generation of three different fragments of bound C3 with purified factor I or serum. II. Location of binding sites in the C3 fragments for factors B and H, complement receptors, and bovine conglutinin.
Ross GD; Newman SL; Lambris JD; Devery-Pocius JE; Cain JA; Lachmann PJ
J Exp Med; 1983 Aug; 158(2):334-52. PubMed ID: 6224880
[TBL] [Abstract][Full Text] [Related]
8. Epstein Barr virus/complement C3d receptor is an interferon alpha receptor.
Delcayre AX; Salas F; Mathur S; Kovats K; Lotz M; Lernhardt W
EMBO J; 1991 Apr; 10(4):919-26. PubMed ID: 1849076
[TBL] [Abstract][Full Text] [Related]
9. Cell cycle control of a Burkitt lymphoma cell line: responsiveness to growth signals engaging the C3D/EBV receptor.
Pernegger G; Schulz TF; Hosp M; Myones BL; Petzer AL; Eigentler A; Böck G; Wick G; Dierich MP
Immunology; 1988 Oct; 65(2):237-41. PubMed ID: 2461345
[TBL] [Abstract][Full Text] [Related]
10. Structure-guided identification of C3d residues essential for its binding to complement receptor 2 (CD21).
Clemenza L; Isenman DE
J Immunol; 2000 Oct; 165(7):3839-48. PubMed ID: 11034390
[TBL] [Abstract][Full Text] [Related]
11. Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g.
Davis AE; Harrison RA; Lachmann PJ
J Immunol; 1984 Apr; 132(4):1960-6. PubMed ID: 6607952
[TBL] [Abstract][Full Text] [Related]
12. Identification of a spontaneously shed fragment of B cell complement receptor type two (CR2) containing the C3d-binding site.
Myones BL; Ross GD
Complement; 1987; 4(2):87-98. PubMed ID: 3497773
[TBL] [Abstract][Full Text] [Related]
13. Segment spanning residues 727-768 of the complement C3 sequence contains a neoantigenic site and accommodates the binding of CR1, factor H, and factor B.
Becherer JD; Alsenz J; Esparza I; Hack CE; Lambris JD
Biochemistry; 1992 Feb; 31(6):1787-94. PubMed ID: 1371073
[TBL] [Abstract][Full Text] [Related]
14. Neutrophils express a receptor for iC3b, C3dg, and C3d that is distinct from CR1, CR2, and CR3.
Vik DP; Fearon DT
J Immunol; 1985 Apr; 134(4):2571-9. PubMed ID: 3156185
[TBL] [Abstract][Full Text] [Related]
15. Mutation of residues in the C3dg region of human complement component C3 corresponding to a proposed binding site for complement receptor type 2 (CR2, CD21) does not abolish binding of iC3b or C3dg to CR2.
Diefenbach RJ; Isenman DE
J Immunol; 1995 Mar; 154(5):2303-20. PubMed ID: 7868901
[TBL] [Abstract][Full Text] [Related]
16. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d.
Nemerow GR; Mold C; Schwend VK; Tollefson V; Cooper NR
J Virol; 1987 May; 61(5):1416-20. PubMed ID: 3033269
[TBL] [Abstract][Full Text] [Related]
17. A discontinuous factor H binding site in the third component of complement as delineated by synthetic peptides.
Lambris JD; Avila D; Becherer JD; Müller-Eberhard HJ
J Biol Chem; 1988 Aug; 263(24):12147-50. PubMed ID: 2969896
[TBL] [Abstract][Full Text] [Related]
18. gp140, a C3b-binding membrane component of lymphocytes, is the B cell C3dg/C3d receptor (CR2) and is distinct from the neutrophil C3dg receptor (CR4).
Frade R; Myones BL; Barel M; Krikorian L; Charriaut C; Ross GD
Eur J Immunol; 1985 Dec; 15(12):1192-7. PubMed ID: 3878789
[TBL] [Abstract][Full Text] [Related]
19. Identification of a partial cDNA clone for the C3d/Epstein-Barr virus receptor of human B lymphocytes: homology with the receptor for fragments C3b and C4b of the third and fourth components of complement.
Weis JJ; Fearon DT; Klickstein LB; Wong WW; Richards SA; de Bruyn Kops A; Smith JA; Weis JH
Proc Natl Acad Sci U S A; 1986 Aug; 83(15):5639-43. PubMed ID: 3016712
[TBL] [Abstract][Full Text] [Related]
20. Structural and functional analysis of CR2/EBV receptor by means of monoclonal antibodies and limited tryptic digestion.
Petzer AL; Schulz TF; Stauder R; Eigentler A; Myones BL; Dierich MP
Immunology; 1988 Jan; 63(1):47-53. PubMed ID: 2448232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]